FDA OKs Novavax COVID Vaccine as First Booster Shot

By Cara Murez 

HealthDay Reporter

THURSDAY, Oct. 20, 2022 (HealthDay News) – Americans will now have one other alternative if they need a COVID booster shot.

On Wednesday, the U.S. Food and Drug Administration accredited Novavax Inc.’s protein-based vaccine as a primary booster dose. Until now, it had solely been accredited as a two-dose main sequence.

“The U.S. now has access to the Novavax COVID-19 Vaccine, adjuvanted, the first protein-based option, as a booster,” Novavax President and CEO Stanley Erck mentioned in a information launch. “According to CDC data, almost 50 percent of adults who received their primary series have yet to receive their first booster dose. Offering another vaccine choice may help increase COVID-19 booster vaccination rates for these adults.”

The Novavax booster may very well be utilized by adults who can’t discover or usually are not in a position to make use of an mRNA boosters from Pfizer or Moderna. It’s additionally accessible to individuals who want this vaccine for a booster over the mRNA choices. The Novavax booster could be given at the very least six months after the first sequence.

The Novavax vaccine makes use of a extra conventional strategy to combating the virus, instructing the immune system to acknowledge modified fragments of the coronavirus spike protein.

Scientists created the vaccine from a genetic sequence of the unique pressure of the virus. Vaccines that struggle hepatitis B and pertussis are additionally made on this method.

Public well being officers are encouraging individuals to get their boosters. About 68% of U.S. residents have had an preliminary COVID vaccine sequence, however solely 33.5% have acquired boosters, CDC information exhibits. Novavax’s vaccine is one in all 4 choices accessible within the United States now.

More info

The U.S. Centers for Disease Control and Prevention has extra on COVID-19 vaccines.

 

 

SOURCE: CNN